Dr. Sairam Parthasarathy, a professor in the University of Arizona College of Medicine – Tucson and member of the university's BIO5 Institute, discusses the state of sleep health today and how UArizona researchers are contributing to a future of better sleep.

Ricardo Correa, MD, program director of endocrinology fellowship and director for diversity at the University of Arizona College of Medicine – Phoenix, and colleagues provide perspective on the historical structural racism that has contributed to how disparities in diabetes are viewed by the medical establishment.

Scientific experts from across the United States will be answering the public's questions on the COVID-19 vaccine as more vaccines become available. University of Arizona College of Medicine – Tucson virologist Felicia Goodrum Sterling is a co-chair of this town hall series.

In a new report about the status of COVID-19 in Arizona, Joe Gerald, an associate professor in the University of Arizona's Mel and Enid Zuckerman College of Public Health, said that as case positivity continues to decline and the number of vaccine doses continues to rise, Arizona could see herd immunity by late April or early May, adding that herd immunity is based on several factors including "vaccine efficacy, viral transmissible and natural immunity."

On Match Day, about 120 UArizona College of Medicine – Tucson students learned where they’ll launch their careers as new residents after graduation.

Nearly 26% of the Class of 2021 will specialize in primary care; 25% will remain in Phoenix and practice in Arizona-based hospitals.

Experts say local mobile vaccination clinics have been a success in bringing in people of color. Joe Gerald, an associate professor with the University of Arizona's Mel and Enid Zuckerman College of Public Health, is interviewed.

An experimental pill meant to combat COVID-19 could soon be used for widespread treatment. Jun Wang, an associate professor of Pharmacology and Toxicology at the University of Arizona College of Pharmacy, said the clinical trial results look promising.

A new study will examine the impact of COVID-19 on medication for opioid use disorder access and patient health.

A three-day virtual conference brings together experts from the UArizona Health Sciences and Navrachana University in Vadodara, India, to discuss current public health ideas, practice and research.